OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement
April 23, 2019 08:00 ET
|
OmniSeq
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global...
OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial
July 31, 2018 16:05 ET
|
OmniSeq
BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the...
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
June 01, 2018 16:11 ET
|
OmniSeq
CHICAGO, June 01, 2018 (GLOBE NEWSWIRE) -- ASCO – OmniSeq®, a CAP-accredited, molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE:LH), a leading...
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
April 12, 2018 09:00 ET
|
OmniSeq
BUFFALO, N.Y., April 12, 2018 (GLOBE NEWSWIRE) -- OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation...
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
August 21, 2017 08:01 ET
|
OmniSeq
BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it has entered into an exclusive...
Rand Partners With Innovate NY Fund to Invest in Personalized Cancer Medicine Business, Empire Genomics, LLC
July 01, 2014 17:04 ET
|
Rand Capital Corporation
BUFFALO, NY--(Marketwired - Jul 1, 2014) - Rand Capital Corporation (www.randcapital.com) (NASDAQ: RAND) a Buffalo, New York based Business Development Company (BDC) and Small Business Investment...